Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific, including: 3Sbio, Can-Fite, Capricor, Cstone, FSD, Gilead Sciences, Hifibio, Laurent, Revive, Sirtex Medical US, Sound, TLC, Xortx.
Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: Akari, Astrazeneca, Glaxosmithkline, Mereo, Orpheris, Ovid, Redhill, Takeda, Union, Vir.
The latest global regulatory news, changes and updates affecting biopharma, including: Department of Justice, Dusa, FDA, Michbio, Russian Ministry of Health, SEC, Stericycle Expert Solutions, Wintac.
Ever since the Hong Kong Stock Exchange (HKEX) overhauled its listing rules to welcome pre-revenue biotech companies in April 2018, Hong Kong has become the largest biotech fundraising hub in Asia, and the second largest in the world after Nasdaq, HKEX executives said Tuesday at the bourse’s biotech summit. The biotech IPO pipeline continues to grow and pre-revenue companies are more accepted into the city’s financial system.
Biopharmas in Asia-Pacific raising money in public or private financings, including: Bone Therapeutics, Connect Biopharmaceuticals, Opthea, Rnaimmune, Sirnaomics.
The latest global regulatory news, changes and updates affecting biopharma, including: Department of Health and Human Services, Drug Enforcement Administration, FDA, Health Canada, National Center for Advancing Translational Sciences, SK Biopharma.
Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific, including: Aligos, Astrazeneca, Carsgen, Kazia, Kimera Labs, Lidds, Merck, Opthea, Samsung Bioepis, Sorrento.
RSS
